| abstract |
The present invention relates to a group of piperazine and piperidine derivatives of formula (I), wherein Y is a heteroaryl group optionally substituted by one or more halogen, nitro, C1-6alkyl, C1-6alkoxy, aryloxy, arylC1-6alkylenoxy, hydroxy, S(O)nR2 or S(O)¿nN(R?2)2 where n is 0, 1 or 2, CN, CON(R2)2, COR2, CO2R2, CO-aryl, azido, -N(R2)2, -NR2N(R2a)2, -NR?2N = C(R2a)¿2, -NR2(C = O)CH(N(R2a)2)R?2b, -NR2¿(C = O)R?2a, NR2CO¿2R2a, C1-6alkoxycarbonylamino or PhN = N; with the proviso that Y does not include benzisothiazolyls or benzisoxazolyis, V is O or S; Z is C1-8alkylene optionally interrupted by -O- or -S(O)n- where n is 0, 1 or 2, C2-8alkenylene or C2-8alkynylene; X is N, CR?3 or COR3¿; A is CR4 or N; B is oxygen, NR5 or S(O)¿n?, where n is 0, 1 or 2; and R?1¿ is hydrogen or one or more halogen, hydroxy, nitro, CN, NR62, C1-6alkoxy, aryloxy, arylC1-6alkylenoxy, or COR?6, R, R2, R2a, R2b, R3, R4, R5 and R6¿, are each hydrogen or C¿1-6?alkyl; or a salt, solvate, N-oxide or physiologically functional derivative thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their use in therapy, in particular in the treatment of psychotic disorders. |